Research programme: gene therapies - Genetix Pharmaceuticals

Drug Profile

Research programme: gene therapies - Genetix Pharmaceuticals

Alternative Names: LentiDL™; LentiFVIII™; LentiNeur™; LentiRA™; LentiVue™

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genetix Pharmaceuticals
  • Developer bluebird bio; Brigham and Womens Hospital; Columbia University; Harvard University; INSERM
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haemophilia A; Hypercholesterolaemia; Macular degeneration; Neurological disorders; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hypercholesterolaemia in France (Intrahepatic)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Macular-degeneration in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top